In response to the growing complexity of modern therapeutics—such as mRNA vaccines, gene editors, antibody-drug conjugates (ADCs), and extracellular vesicles (EVs)—Litchlab today officially launched its Integrated Drug Carrier CDMO Platform, offering a full suite of solutions from design and formulation to GMP manufacturing and regulatory support.

“Drug carriers are no longer just delivery tools; they are part of the therapeutic strategy,” said Chief Scientific Officer and Co-Founder of Litchlab. “We aim to build carrier systems that are clinical-grade, scalable, and regulatory-ready to help innovative therapies reach patients faster.”

Global Trend: Carriers Become the Second Engine of Drug Design

As therapeutic modalities diversify beyond small molecules—into RNA, proteins, peptides, plasmid DNA, and CRISPR systems—traditional dosage forms can no longer guarantee efficacy or safety. Functional nanocarriers like lipid nanoparticles, polymer micelles, hydrogels, gold nanoparticles, and mesoporous silica are becoming central to formulation innovation and CDMO investments worldwide.

With increasingly stringent expectations from regulatory bodies such as the FDA, EMA, and NMPA, carrier systems must demonstrate reproducibility, biocompatibility, and process scalability from lab to clinical stage—raising the bar for CDMO capabilities.

Litchlab’s Carrier Platform: Six Core Advantages

✅ 1. Diverse Carrier Development Capabilities

• Lipid-based carriers: liposomes, solid lipid nanoparticles (SLNs), hybrid lipid–polymer systems

• Polymer-based carriers: microspheres, nanoparticles, micelles, PLGA/PEG block copolymers

• Inorganic carriers: gold nanoparticles, magnetic nanoparticles, mesoporous silica (MSNs)

• Stimuli-responsive carriers: pH/temperature/enzyme/redox-triggered release systems

• Hybrid systems: lipid-peptide, polymer-protein, multi-modal platforms
  

  
  

✅ 2. Smart Drug Loading Strategies

• Optimized encapsulation efficiency (EE), drug loading (DL), and release kinetics

• Compatible with a broad range of APIs: small molecules, peptides, proteins, antibodies, nucleic acids, mRNA, siRNA, DNA, EVs

• Surface strategies include click chemistry, hydrophobic embedding, electrostatic adsorption, crosslinking, and conjugation
  

  
  

✅ 3. GMP-Compatible Process Scale-Up

• Advanced methods: emulsification-solvent evaporation, thin-film hydration, nanoprecipitation, microfluidics, lyophilization, spray drying

• Smooth scalability: gram → pilot-scale → clinical GMP scale (10+ kg batches)

• Dosage forms supported: injectables, lyophilized powder, gels, lipid emulsions, films
  

  
  

✅ 4. Functional & Targeted Carrier Engineering

• Custom ligand modification: antibodies, peptides, sugars, PEGylation

• Particle size control: 20 nm – 1 μm with tunable PDI and zeta potential

• Stimuli-responsive design for tumor microenvironments, inflammation sites, or intracellular triggers
  

  
  

✅ 5. Full-Spectrum Analytics & Regulatory Support

• Characterization: particle size, zeta potential, stability, encapsulation, release kinetics, cellular uptake, toxicity

• ICH-compliant stability studies and IND/IMPD/NDA documentation preparation
  

  
  

✅ 6. Cross-Platform Integration

• Seamless combination with Litchlab’s hydrogels, microspheres, liposome and nucleic acid platforms

• Enabling multi-functional drug delivery systems for advanced therapeutic pipelines
  

Selected Applications from Global Client Projects

💬 Our Vision

With the launch of its Carrier Specialty Platform, Litchlab solidifies its commitment to high-performance, regulation-aligned, and innovation-driven CDMO services, empowering pharmaceutical partners worldwide.

📩 Want to explore your next carrier-based project with us?
🔗 Visit: www.litchlab.com
📧 Email: sales@litchlab.com